<< InfoSite Home
Effective as First-Line Treatment
Read Patient ProfileFor newly diagnosed moderate or severe patients and those who do not tolerate AChEIs
Proven efficacy in cognition
Significant cognitive benefits at 6 months and 1 year4,21,22
Results of a 24-week, open-label extension study following a 28-week, randomized, multicenter, double-blind, parallel-group, placebo-controlled US study. This study investigated the efficacy and safety of NAMENDA in 175 outpatients with moderate to severe Alzheimer's disease (AD). Results shown are from observed cases (OC) analysis. Patients received treatment with NAMENDA (10 mg BID) or placebo BID for the first 28 weeks, followed by all patients receiving NAMENDA. At week 52, 137 patients (66 NAMENDA, 71 placebo) completed the study.21,22
- NAMENDA provided superior efficacy in cognition vs placebo over the first 28 weeks of the study period (P=0.002)21
- Slowed cognitive decline when patients were switched from placebo at week 28 (P=0.049)22
- NAMENDA provided superior effect in cognition vs a projection of placebo treatment at weeks 40 (P<0.001) and 52 (P=0.003)4,22
* SIB=Severe Impairment Battery. Evaluates cognitive performance in moderate to severe AD. It is a 40-item scale that is scored from 0 (greatest impairment) to 100.23
Proven first-line efficacy in day-to-day function
Proven, sustained benefits in everyday activities over 52 weeks4,21,22
Results of a 24-week, open-label extension study following a 28-week, randomized, multicenter, double-blind, parallel-group, placebo-controlled US study. This study investigated the efficacy and safety of NAMENDA in 175 outpatients with moderate to severe AD. Results shown are from OC analysis. Patients received treatment with NAMENDA (10 mg BID) or placebo BID for the first 28 weeks, followed by all patients receiving NAMENDA. Analyses at weeks 40 and 52 compared active treatment to a projection of placebo. At week 52, 137 patients (66 NAMENDA, 71 placebo) completed the study.4,21,22
- Patients taking NAMENDA had significantly higher functional ability vs placebo at week 28 (P=0.003)21
- NAMENDA significantly slowed functional decline when patients were switched from placebo at week 28 (P=0.021)22
- NAMENDA provided a superior effect in functional ability vs a projection of placebo treatment at weeks 40 (P<0.001) and 52 (P=0.005)4,22
Maintains significantly greater ability to engage in day-to-day
activities20
Results of a randomized, multicenter, double-blind, parallel-group, placebo-controlled US study investigating the efficacy of NAMENDA in 252 patients with moderate to severe AD. Results shown are from OC analysis. ADLs were consolidated into 4 subscales based on a factor analysis. Patients were ≥50 years of age with a Mini-Mental State Examination (MMSE) score of ≥3 to ≤14 points. Patients were randomized to treatment with NAMENDA (10 mg BID) or placebo BID for 28 weeks. At week 28, 181 patients (97 NAMENDA, 84 placebo) completed the study.20,21
- NAMENDA helped patients maintain significantly more autonomy, higher-level functioning, simple motor skills, and ability to do basic activities vs placebo at week 28 (P≤0.05)20
*Alzheimer's Disease Cooperative Study Activities of Daily Living19 (ADCS-ADL19) Inventory: A comprehensive battery of 19 ADL items aimed at measuring the functional ability of patients with moderate to severe AD. ADCS-ADL19 item responses range from total independence to total disability.15
Important Safety Information
NAMENDA® (memantine HCl) is indicated for the treatment of moderate to severe Alzheimer's disease. NAMENDA has been used by more than 2 million people worldwide.NAMENDA is contraindicated in patients with known hypersensitivity to memantine HCl or any excipients used in the formulation. The most common adverse events reported with NAMENDA vs placebo (≥5% and higher than placebo) were dizziness, confusion, headache, and constipation. In patients with severe renal impairment, the dosage should be reduced.
See Full Prescribing Information